Selectivity among dipeptidyl peptidases of the S9b family

Cellular and Molecular Biology

Volumn 52, Issue 4, 2006, Pages 3-7

  Bjelke, J R ^a   Kanstrup, A B ^a   Rasmussen, H B ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Dipeptidyl peptidase; Neuropeptide Y; Peptide YY; S9b family; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE 8; DIPEPTIDYL PEPTIDASE 9; DIPEPTIDYL PEPTIDASE IV; NEUROPEPTIDE Y; PEPTIDE YY; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; CONFERENCE PAPER; ENZYME KINETICS; ENZYME SUBSTRATE; PROTEIN DEGRADATION; PROTEIN STRUCTURE; SEQUENCE ANALYSIS;

ANIMALS; ANTIGENS, CD26; BINDING SITES; ISOENZYMES; MODELS, MOLECULAR; NEUROPEPTIDE Y; PEPTIDE YY; PROTEIN STRUCTURE, TERTIARY; SUBSTRATE SPECIFICITY;

EID: 34247588747     PISSN: 01455680     EISSN: 1165158X     Source Type: Journal    
DOI: 10.1170/T720     Document Type: Conference Paper

References (28)

1. Aertgeerts K., Ye S., Tennant M.G., Kraus M.L., Rogers J., Sang B.C., Skene R.J., Webb D.R. and Prasad G.S., Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation. Protein Sci. 2004, 13: 412-421.
2. Ahren B., Gomis R., Standl E., Mills D. and Schweizer A., Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004, 27: 2874-2880.
3. Ahren B., Landin-Olsson M., Jansson P.A., Svensson M., Holmes D. and Schweizer A., Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J. Clin. Endocrinol. Metab. 2004 89: 2078-2084.
4. Ahren B., Simonsson E., Larsson H., Landin-Olsson M., Torgeirsson H., Jansson P.A., Sandqvist M., Bavenholm P., Efendic S., Eriksson J.W., Dickinson S. and Holmes D., Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care. 2002, 25:869-75.
5. Ajami, K., Abbott, C.A., McCaughan, G.W. and Gorrell, M.D., Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim. Biophys. Acta. 2004, 1679: 18-28.
6. Bjelke J.R., Christensen J., Branner S., Wagtmann N., Olsen C., Kanstrup A.B. and Rasmussen H.B., Tyrosine 547 constitutes an essential part of the catalytic mechanism of dipeptidyl peptidase IV. J. Biol. Chem. 2004, 279: 34691-34697.
7. Bjelke J.R., Christensen J., Nielsen P.F., Branner S., Kanstrup A.B., Wagtmann N. and Rasmussen H.B., Dipeptidyl peptidase 8 and 9 specificity and molecular characterization compared to dipeptidyl peptidase IV. Biochem. J. 2006, In press.
8. Cheng J.D., Dunbrack R.L. Jr., Valianou M., Rogatko A., Alpaugh R.K. and Weiner L.M., Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res. 2002, 62: 4767-4772.
9. Conarello S.L., Li Z., Ronan J., Roy R.S., Zhu L., Jiang G., Liu F., Woods J., Zycband E., Moller D.E., Thornberry N.A. and Zhang B.B., Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 2003 100: 6825-6830.
10. Gorrell M.D., Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond). 2005, 108: 277-292.
11. Holst J.J. and Deacon C.F., Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes. 1998, 47: 1663-1670.
12. Hopsu-Havu, V.K. and Glenner, G.G., A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-betanaphthylamide. Histochemie. 1966, 7: 197-201.
13. Jiaang W.T., Chen Y.S., Hsu T., Wu S.H., Chien C.H., Chang C.N., Chang S.P., Lee S.J. and Chen X., Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8. Bioorg. Med. Chem. Lett. 2005, 15: 687-691.
14. Kenny, A.J., Booth, A.G., George, S.G., Ingram, J., Kershaw, D., Wood, E.J. and Young, A.R. Dipeptidyl peptidase IV, a kidney brush-border serine peptidase. Biochem. J. 1976, 157: 169-182.
15. Kim D., Wang L., Beconi M., Eiermann G.J., Fisher M.H., He H., Hickey G.J., Kowalchick J.E., Leiting B., Lyons K., Marsilio F., McCann M.E., Patel R.A., Petrov A., Scapin G., Patel S.B., Roy R.S., Wu J.K., Wyvratt M.J., Zhang B.B., Zhu L., Thornberry N.A. and Weber A.E., (2R)-4-oxo-4-[3-(trifluoromethyl)- 5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 2005, 48: 141-151.
16. Kieffer T.J., McIntosh C.H. and Pederson R.A., Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995, 136: 3585-3596.
17. Lambeir A.M., Durinx C., Proost P., Van Damme J., Scharpe S. and De Meester I., Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion. FEBS Lett. 2001, 507: 327-330. Erratum in: FEBS Lett. 2002, 512(1-3): 353.
18. Lankas G.R., Leiting B., Roy R.S., Eiermann G.J., Beconi M.G., Biftu T., Chan C.C., Edmondson S., Feeney W.P., He H., Ippolito D.E., Kim D., Lyons K.A., Ok H.O., Patel R.A., Petrov A.N., Pryor K.A., Qian X., Reigle L., Woods A., Wu J.K., Zaller D., Zhang X., Zhu L., Weber A.E. and Thornberry N.A., Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 2005 54: 2988-2994.
19. Lu I.L., Lee S.J., Tsu H., Wu S.Y., Kao K.H., Chien C.H., Chang Y.Y., Chen Y.S., Cheng J.H., Chang C.N., Chen T.W., Chang S.P., Chen X. and Jiaang W.T., Glutamic acid analogues as potent dipeptidyl peptidase IV and 8 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15: 3271-3275.
20. Marguet D., Baggio L., Kobayashi T., Bernard A.M., Pierres M., Nielsen P.F., Ribel U., Watanabe T., Drucker D.J. and Wagtmann N., Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. U.S.A. 2000, 97: 6874-6879.
21. Medeiros Mdos S. And Turner A.J., Metabolism and functions of neuropeptide Y. Neurochem. Res. 1996, 21: 1125-1132.
22. Mentlein R., Gallwitz B. and Schmidt W.E., Dipeptidylpeptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum., Eur. J. Biochem. 1993, 15: 829-835.
23. Park J.E., Lenter M.C., Zimmermann R.N., Garin-Chesa P., Old L.J., Rettig W.J., Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J. Biol. Chem. 1999, 274: 36505-36512.
24. Puschel, G., Mentlein, R. and Heymann, E., Isolation and characterization of dipeptidyl peptidase IV from human placenta. Eur. J. Biochem. 1982, 126: 359-365.
25. Rasmussen H.B., Branner S., Wiberg F.C. and Wagtmann N., Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat. Struct. Biol. 2003, 10:19-25.
26. Rawlings, N.D. and Barrett, A.J., MEROPS: the peptidase database. Nucleic. Acids Res. 1999, 27: 325-331.
27. Schechter, I. and Berger, A., On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 1967, 27: 157-162.
28. Tsu H., Chen X., Chen C.T., Lee S.J., Chang C.N., Kao K.H., Coumar M.S., Yeh Y.T., Chien C.H., Wang H.S., Lin K.T., Chang Y.Y., Wu S.H., Chen Y.S., Lu I.L., Wu S.Y., Tsai T.Y., Chen W.C., Hsieh H.P., Chao Y.S. and Jiaang W.T., 2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]- 1,2,3,4-tetrahydroisoquinoline: a potent, selective, and orally bioavailable dipeptidederived inhibitor of dipeptidyl peptidase IV. J. Med. Chem. 2006, 49: 373-380.